Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination strategies, in the treatment of ER+/HER2− metastatic breast cancer. Drs. Jhaveri and Kaklamani review emerging efficacy and safety data, considerations for treatment selection after prior endocrine therapy and CDK4/6 inhibitor exposure, the role of ESR1 mutation testing in sequencing therapy, and emerging combination and frontline treatment data. The discussion also highlights practical, interdisciplinary approaches to monitoring and managing adverse events to support evidence-based clinical decision-making in practice.
Update: On September 4, 2026, the FDA granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on an FDA-authorized test.
Update: On September 18, 2026, the FDA approved imlunestrant in combination with abemaciclib, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AXIS designates this activity for 0.50 contact hour(s)/0.05 CEUs of pharmacy contact hour(s). 
AXIS has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit(s). Approval is valid until 08/28/27. PAs should claim only the credit commensurate with the extent of their participation in the activity.
